Evidence map›Paper›PMID 22198310›Full record

Trial reportCancer immunology, immunotherapy : CII2012

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.

Katayoun Rezvani, Agnes S M Yong, Stephan Mielke, Bipin N Savani, Behnam Jafarpour, Rhoda Eniafe, Robert Quan Le, Laura Musse, Carole Boss, Richard Childs and 1 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Article
  4. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Article
  5. Review
  6. Article
  7. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Katayoun RezvaniHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. k.rezvani@imperial.ac.uk
Agnes S M Yong
Stephan Mielke
Bipin N Savani
Behnam Jafarpour
Rhoda Eniafe
Robert Quan Le
Laura Musse
Carole Boss
Richard Childs
A John Barrett
National Institutes of Health · USNational Heart Lung and Blood Institute · USImperial College London · GBUniversity of Würzburg · DE

Funding

Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZIAHL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2009 to 2025
$53.3M
Graft-versus-leukemiaZIAHL002342 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BARRETT, AUSTIN JOHN · 2009 to 2010
$6.3M
Intramural NIH HHS ZIA HL002342
6 · The paper itself

Abstract

PR1, an HLA-A*0201 epitope shared by proteinase-3 (PR3) and elastase (ELA2) proteins, is expressed in normal neutrophils and overexpressed in myeloid leukemias. PR1-specific T cells have been linked to graft-versus-leukemia (GVL) effect. We hypothesized that lymphopenia induced by chemo-radiotherapy can enhance weak autoimmune responses to self-antigens such as PR1. We measured PR1-specific responses in 27 patients 30-120 days following allogeneic stem cell transplant (SCT) and correlated these with ELA2 and PR3 expression and minimal residual disease (MRD). Post-SCT 10/13 CML, 6/9 ALL, and 4/5 solid tumor patients had PR1 responses correlating with PR3 and ELA2 expression. At day 180 post-SCT, 8/8 CML patients with PR1 responses were BCR-ABL-negative compared with 2/5 BCR-ABL-positive patients (P = 0.025). In contrast, PR1 responses were detected in 2/4 MRD-negative compared with 4/5 MRD-positive ALL patients (P = 0.76). To assess whether the lymphopenic milieu also exaggerates weak T-cell responses in the autologous setting, we measured spontaneous induction of PR1 responses in 3 AML patients vaccinated with WT1-126 peptide following lymphodepletion. In addition to WT1-specific T cells, we detected PR1-specific T cells in 2 patients during hematopoietic recovery. Our findings suggest that lymphopenia induced by chemo-radiotherapy enhances weak autoimmune responses to self-antigens, which may result in GVL if the leukemia expresses the relevant self-antigen.

Indexed as

AdolescentAdultAgedAged, 80 and overCancer VaccinesCase-Control StudiesCombined Modality TherapyFemaleHematopoietic Stem Cell TransplantationHLA-A2 AntigenHumansLeukemia, Myeloid, AcuteLymphocyte DepletionMaleMiddle AgedOligopeptidesCancer VaccinesHLA-A*02:01 antigenHLA-A2 AntigenOligopeptidesRMFPNAPYLVaccines, SubunitWT1 Proteins

Identifiers

PMID22198310
PMCPMC4163946
OpenAlexW2005234504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.